EMCDDA Home
  • EN
Search

Figure GPS-20. Lifetime and last 12 months prevalence of cocaine use among young adults (aged 15–34) in Europe, Canada, Australia and the USA

 
 
CountryLifetime prevalenceLast 12 months prevalence
Related links:
Belgium (2008)
Romania (2010)0.7
Lithuania (2008)0.7
Malta (2001)0.9
Greece (2004)1.0
Slovakia (2010)1.1
Hungary (2007)1.8
Latvia (2011)2.2
Poland (2010)2.3
Czech Republic (2011)2.5
Finland (2010)2.6
Austria (2008)2.8
Portugal (2007)2.8
Bulgaria (2008)3.0
Croatia (2012)3.8
Norway (2009)4.2
Sweden (2008)4.6
Germany (2009)5.0
Cyprus (2009)5.3
France (2010)6.0
EU average6.1
Italy (2012)6.5
Netherlands (2009)7.6
Canada (2010)8.6
Denmark (2010)8.9
Ireland (2010/11)9.4
Spain (2011)11.1
Australia (2010)11.6
United Kingdom (2011/12)13.6
USA (2010)15.4
Belgium (2008)0.2
Romania (2010)0.2
Lithuania (2008)0.3
Malta (2001)
Greece (2004)0.2
Slovakia (2010)0.4
Hungary (2007)0.4
Latvia (2011)0.3
Poland (2010)1.3
Czech Republic (2011)1.1
Finland (2010)0.6
Austria (2008)1.2
Portugal (2007)1.2
Bulgaria (2008)1.5
Croatia (2012)0.9
Norway (2009)0.6
Sweden (2008)1.2
Germany (2009)1.8
Cyprus (2009)2.1
France (2010)1.9
EU average1.9
Italy (2012)1.3
Netherlands (2009)2.4
Canada (2010)1.8
Denmark (2010)2.5
Ireland (2010/11)2.8
Spain (2011)3.6
Australia (2010)4.8
United Kingdom (2011/12)4.2
USA (2010)4.1
Statistical bulletin 2006: Figure GPS-21
Statistical bulletin 2007: Figure GPS-20
Statistical bulletin 2008: Figure GPS-20
Statistical bulletin 2009: Figure GPS-20
Statistical bulletin 2010: Figure GPS-20
Statistical bulletin 2011: Figure GPS-20
Statistical bulletin 2012: Figure GPS-20
See also Tables GPS-1 part iii
See also 'General notes for interpreting data' on the Explanatory notes and help page.

Notes:

Data are from the most recent national surveys available in each country (see General population survey tables, Statistical bulletin 2013).

Countries have been sorted according to lifetime prevalence of cocaine.

In the European Member States, most surveys were conducted between 2007 and 2011, and the standard age range is 15 to 34 (in some countries the lower end may be 16 or 18 years).

The European average prevalence rate was calculated as the average of the national prevalence rates weighted by national population of 15- to 34-year olds (2011, taken from Eurostat).

In the USA, the survey was conducted in 2010, and the age range is 16 to 34 years (recalculated from original data).

In Canada, the survey was conducted in 2010, and the age range is 15 to 34 years.

For Australia, the survey was conducted in 2010, and the age range is 15 to 34 years.

Variations in age ranges may slightly influence disparities between countries.

The most recent general population survey reported by the Netherlands display a wide variation in results compared with 2005 which may reflect methodological differences. The data is provided for information, but given the lack of comparability between surveys should be treated with caution.

The most recent general population survey reported by Italy display a wide variation in results compared with the previous surveys which may reflect methodological differences. The data is provided for information, but given the lack of comparability between surveys should be treated with caution.

Sources:

Reitox national reports 2012, taken from population surveys, reports or scientific articles.

Canada: CADUMS, Canadian Alcohol and Drug Use Monitoring Survey (CADUMS, 2010)

USA: SAMHSA, Office of Applied Studies, National survey on drug use and health, 2010.

Australian Institute of Health and Welfare 2010. 2010 National Drug Strategy Household Survey: detailed findings. Canberra: AIHW http://www.aihw.gov.au/publication-detail/?id=32212254712&tab=2

Country Lifetime prevalence Last 12 months prevalence
Belgium (2008)   0.2
Romania (2010) 0.7 0.2
Lithuania (2008) 0.7 0.3
Malta (2001) 0.9  
Greece (2004) 1.0 0.2
Slovakia (2010) 1.1 0.4
Hungary (2007) 1.8 0.4
Latvia (2011) 2.2 0.3
Poland (2010) 2.3 1.3
Czech Republic (2011) 2.5 1.1
Finland (2010) 2.6 0.6
Austria (2008) 2.8 1.2
Portugal (2007) 2.8 1.2
Bulgaria (2008) 3.0 1.5
Croatia (2012) 3.8 0.9
Norway (2009) 4.2 0.6
Sweden (2008) 4.6 1.2
Germany (2009) 5.0 1.8
Cyprus (2009) 5.3 2.1
France (2010) 6.0 1.9
EU average 6.1 1.9
Italy (2012) 6.5 1.3
Netherlands (2009) 7.6 2.4
Canada (2010) 8.6 1.8
Denmark (2010) 8.9 2.5
Ireland (2010/11) 9.4 2.8
Spain (2011) 11.1 3.6
Australia (2010) 11.6 4.8
United Kingdom (2011/12) 13.6 4.2
USA (2010) 15.4 4.1

gpsfig20

 

About the EMCDDA

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU's decentralised agencies. Read more >>

Contact us

EMCDDA
Praça Europa 1, Cais do Sodré
1249-289 Lisbon
Portugal
Tel. (351) 211 21 02 00
Fax (351) 218 13 17 11

More contact options >>

Page last updated: Tuesday, 07 May 2013